Coronavirus: Ose Immunotherapeutics vaccine delivers encouraging results

Published by Laurent P. · Published on 6 November 2020 at 18h04 · Updated on 9 November 2020 at 11h28
French laboratory Ose Immunotherapeutics has released encouraging results as for candidate vaccine against coronavirus, adding they will initiate the clinical phase in the first quarter of the year 2021.

Slow and steady wins the race… A motto that Nantes-based Ose Immunotherapeutics pharmaceutical group seems to follow as they unveil their candidate vaccine against coronavirus has been delivering encouraging results so far. They announce in a release they have achieved in human ex vivo study, led by CoVepiT, the “prophylactic vaccine against Covid-19”.

A study led in 120 adults recovering from Covid-19 and other people not exposed to the disease that reached its goal, naming initiating the clinical phase “expected to start end of 2020/early 2021”. The French laboratory joined AstraZeneca, Sinovac, Pfizer/BioNTech and even Sanofi and Moderna Therapeutics in the race for a vaccine, but specifically authorized or on-going clinical trials.

What does this candidate vaccine consist in? It is based on optimized epitopes (a molecule than can be recognized by a paratope, a receptor found on the surface of specific antiborides and that can stimulate the production of this antibody) selected to induce a lasting immune response of lymphocytes T, a genuine memory of viruses in the human body, against Covid-19.

A statement accompanied by the presentation of their multi-target and anti-Covid vaccine during the World Immunotherapy Congress held from November 2 to 9, 2020. This is the very first time a second-generation vaccine against coronavirus is presented during a scientific event.

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search